Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 48.00
Change Today 0.00 / 0.00%
Volume 0.0
VAXL On Other Exchanges
Tel Aviv
As of 10:24 AM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

vaxil bio ltd (VAXL) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/13/14 - $116.05
52 Week Low
01/5/15 - $30.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VAXIL BIO LTD (VAXL)

Related News

No related news articles were found.

vaxil bio ltd (VAXL) Related Businessweek News

No Related Businessweek News Found

vaxil bio ltd (VAXL) Details

Vaxil Bio Ltd., a clinical stage biotechnology company, engages in the development of novel, immunotherapeutic products, peptides, and antibodies for the treatment of cancer and infectious diseases in Israel. The company’s lead product is ImMucin, a multi-epitope cancer vaccine to the MUC1 tumor associated antigen that has been completed Phase I/II clinical trials in multiple myeloma patients; and is in Phase I/II clinical trials for the treatment of metastatic breast cancer patients in combination with hormonal therapy. It also develops MTbuVax, a multi-antigenic and multi-epitope subunit vaccine, which is in preclinical stage to treat intracellular pathogenic bacteria mycobacterium tuberculosis; and SPmAb-2.1 and SPmAb-6 monoclonal antibodies for the treatment of MUC1 SP domain. The company has partnership agreements with Hadassah Medical Center, Rambam Medical Center, Tel-Aviv University, USC, Harvard, Bar-Ilan University, Maccabi Health Organization, Kaplan Medical Center, and Immunovaccine. Vaxil Bio Ltd. was founded in 2006 and is headquartered in Ness Ziona, Israel.

Founded in 2006

vaxil bio ltd (VAXL) Top Compensated Officers

Founder, Chief Executive Officer and Head of ...
Total Annual Compensation: 848.0K
President and Chief Financial Officer
Total Annual Compensation: 726.0K
Compensation as of Fiscal Year 2014.

vaxil bio ltd (VAXL) Key Developments

US Food and Drug Administration Grants Orphan Drug Designation to Vaxil Bio's ImMucin

Vaxil Bio reported that its lead product, ImMucin, has been granted an 'orphan drug' designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma (MM). ImMucin is an immunotherapeutic treatment which educates the MM patient's immune system, particularly T-cells and antibodies, to attack MM cancer cells via a specific domain, termed signal peptide, of the tumor marker MUC1. This domain bears significant advantages as an immunotherapeutic modality. Immunotherapy as a cancer treatment modality has become an important field of medicine during the last two years. It has been the subject of great interest, as drugs that utilize the mechanisms of the immune system have been shown to produce results with far-reaching consequences, and have turned out to be 'game changers' in the treatment of this disease. Orphan drug designation is granted by the FDA in order to promote the clinical development of drugs and treatments with significant treatment potential against rare (fewer than 200,000 people in the US) life-threatening diseases. 'Orphan drug' designation grants the exclusivity to market in the US for 7 years from the moment the approval is provided.

Vaxil Bio Ltd, Special/Extraordinary Shareholders Meeting, Jul 06, 2014

Vaxil Bio Ltd, Special/Extraordinary Shareholders Meeting, Jul 06, 2014., at 12:00 Israel Standard Time.

Vaxil Bio Ltd, Special/Extraordinary Shareholders Meeting, May 04, 2014

Vaxil Bio Ltd, Special/Extraordinary Shareholders Meeting, May 04, 2014., at 12:00 Israel Standard Time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VAXL:IT 48.00 0.00

VAXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAXL.
View Industry Companies

Industry Analysis


Industry Average

Valuation VAXL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VAXIL BIO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at